CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants

Lerche, stefanie; Wurster, Isabel; Valente, Enza Maria; Avenali, Micol; Samaniego Toro, Daniela; Laguna Tuset, Ariadna; HERNANDEZ-VARA, JORGE

View

CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants, 2024 (634.4Kb)

Author

Samaniego Toro, Daniela

Laguna Tuset, Ariadna

HERNANDEZ-VARA, JORGE

Date

2024-10-24

Permanent link

https://hdl.handle.net/11351/12354

DOI

10.1038/s41531-024-00820-0

ISSN

2373-8057

WOS

001340649400003

PMID

39448669

Show full item record

Abstract

Variants in GBA1 result in dysregulated sphingolipids. We investigated five CSF d18:1 sphingolipid species in a longitudinal multicenter cohort comprising people with Parkinson’s Disease and Dementia with Lewy bodies with and without GBA1 variants and healthy controls. We found no increase of sphingolipid species in heterozygous GBA1 variant participants and no effect on development of cognitive impairment. Thus, CSF d18:1 sphingolipids are not suitable as state markers in Parkinson’s Disease.

Keywords

Sphingolipid; Parkinson disease; Dementia with Lewy bodies

Bibliographic citation

Lerche S, Wurster I, Valente EM, Avenali M, Samaniego D, Martínez-Vicente M, et al. CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants. npj Park Dis. 2024 Oct 24;10:198.